Trial Profile
Phase 1b, open-Label, dose escalation study of quizartinib in combination with induction and consolidation chemotherapy in Japanese patients with newly diagnosed acute myeloid leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 26 Jan 2018 Status changed from active, no longer recruiting to completed.
- 14 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 May 2018.
- 13 Nov 2017 Planned End Date changed from 31 Dec 2017 to 30 Jun 2018.